Assembly Biosciences ROA 2010-2024 | ASMB
Current and historical return on assets (ROA) values for Assembly Biosciences (ASMB) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Assembly Biosciences ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-09-30 |
$-0.04B |
$0.10B |
-34.75% |
| 2024-06-30 |
$-0.05B |
$0.12B |
-42.45% |
| 2024-03-31 |
$-0.05B |
$0.12B |
-54.26% |
| 2023-12-31 |
$-0.06B |
$0.14B |
-71.98% |
| 2023-09-30 |
$-0.07B |
$0.05B |
-94.74% |
| 2023-06-30 |
$-0.08B |
$0.07B |
-86.63% |
| 2023-03-31 |
$-0.09B |
$0.08B |
-78.22% |
| 2022-12-31 |
$-0.09B |
$0.10B |
-69.43% |
| 2022-09-30 |
$-0.13B |
$0.12B |
-84.01% |
| 2022-06-30 |
$-0.13B |
$0.14B |
-67.56% |
| 2022-03-31 |
$-0.13B |
$0.16B |
-58.27% |
| 2021-12-31 |
$-0.13B |
$0.19B |
-53.01% |
| 2021-09-30 |
$-0.11B |
$0.25B |
-40.63% |
| 2021-06-30 |
$-0.09B |
$0.26B |
-32.92% |
| 2021-03-31 |
$-0.06B |
$0.28B |
-21.32% |
| 2020-12-31 |
$-0.06B |
$0.28B |
-20.72% |
| 2020-09-30 |
$-0.05B |
$0.31B |
-15.95% |
| 2020-06-30 |
$-0.07B |
$0.30B |
-24.59% |
| 2020-03-31 |
$-0.10B |
$0.31B |
-35.06% |
| 2019-12-31 |
$-0.10B |
$0.34B |
-36.84% |
| 2019-09-30 |
$-0.10B |
$0.22B |
-39.11% |
| 2019-06-30 |
$-0.09B |
$0.24B |
-35.74% |
| 2019-03-31 |
$-0.10B |
$0.26B |
-42.86% |
| 2018-12-31 |
$-0.09B |
$0.27B |
-42.87% |
| 2018-09-30 |
$-0.07B |
$0.28B |
-36.27% |
| 2018-06-30 |
$-0.06B |
$0.14B |
-40.07% |
| 2018-03-31 |
$-0.05B |
$0.16B |
-32.14% |
| 2017-12-31 |
$-0.04B |
$0.17B |
-31.97% |
| 2017-09-30 |
$-0.05B |
$0.11B |
-44.54% |
| 2017-06-30 |
$-0.05B |
$0.12B |
-44.83% |
| 2017-03-31 |
$-0.05B |
$0.13B |
-41.92% |
| 2016-12-31 |
$-0.05B |
$0.10B |
-40.18% |
| 2016-09-30 |
$-0.04B |
$0.11B |
-33.88% |
| 2016-06-30 |
$-0.04B |
$0.12B |
-27.96% |
| 2016-03-31 |
$-0.03B |
$0.12B |
-24.31% |
| 2015-12-31 |
$-0.03B |
$0.13B |
-20.83% |
| 2015-09-30 |
$-0.03B |
$0.14B |
-21.86% |
| 2015-06-30 |
$-0.03B |
$0.15B |
-29.95% |
| 2015-03-31 |
$-0.03B |
$0.14B |
-35.74% |
| 2014-12-31 |
$-0.02B |
$0.07B |
-51.98% |
| 2014-09-30 |
$-0.02B |
$0.06B |
-69.17% |
| 2014-06-30 |
$-0.02B |
$0.02B |
-64.76% |
| 2014-03-31 |
$-0.02B |
$0.02B |
-68.38% |
| 2013-12-31 |
$-0.02B |
$0.03B |
-61.54% |
| 2013-09-30 |
$-0.02B |
$0.03B |
-58.06% |
| 2013-06-30 |
$-0.02B |
$0.03B |
-62.07% |
| 2013-03-31 |
$-0.02B |
$0.04B |
-72.07% |
| 2012-12-31 |
$-0.02B |
$0.02B |
-91.43% |
| 2012-09-30 |
$-0.04B |
$0.02B |
-128.93% |
| 2012-06-30 |
$-0.04B |
$0.03B |
-106.67% |
| 2012-03-31 |
$-0.04B |
$0.03B |
-120.30% |
| 2011-12-31 |
$-0.04B |
$0.04B |
-120.69% |
| 2011-09-30 |
$-0.03B |
$0.05B |
-110.64% |
| 2011-06-30 |
$-0.02B |
$0.01B |
-214.63% |
| 2011-03-31 |
$-0.02B |
$0.01B |
-234.48% |
| 2010-12-31 |
$-0.02B |
$0.02B |
-426.67% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.100B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
